Clinical trials: Pancreatic Disorders
Pancreatic Adenocarcinoma, Pancreatic Cancer
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer.
- Trial name
- PaTK01 (NCT00638612)
- Testing
- AdV-tk, Valacyclovir
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Candel Therapeutics, Inc.
Colorectal Cancer, Esophageal Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
- Trial name
- NCT05415475
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in…
- Trial name
- NCT07503028
- Testing
- CRG002
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Celregen Therapeutics
Solid Tumor, Colorectal Cancer
PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
Part 1: This clinical study will first test the safety and initial effect on the tumour of PS101-mediated ACT when given in combination with standard of care chemotherapy in patients with liver metastases (initially those with…
- Trial name
- ACT (NCT04021277)
- Testing
- 20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
- Where
- 4 sites in Norway, United Kingdom
- Volunteers
- 11 people
- Sponsor
- EXACT Therapeutics AS
Pancreatic Neoplasms, Digestive System Neoplasms
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared…
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- apact (NCT01964430)
- Testing
- nab-Paclitaxel, Gemcitabine
- Where
- 341 sites in United States, Australia and 19 more
- Volunteers
- 866 people
- Sponsor
- Celgene
Exocrine Pancreatic Insufficiency
Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
The overall purpose of this research is to demonstrate (or measure) the intestinal availability of lipase, amylase, and protease (enzymes the body has a shortage of) from PANCRECARB® when administered with a meal.
- Trial name
- NCT00749099
- Testing
- pancrelipase
- Volunteers
- 11 people
- Sponsor
- Digestive Care, Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Pancreas, Adenocarcinoma
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and…
- Trial name
- LAPC-BC-819 (NCT01413087)
- Testing
- Biological/Vaccine: BC-819
- Where
- 9 sites in United States, Israel
- Volunteers
- 12 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Cystic Fibrosis
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03447249
- Testing
- VX-659/TEZ/IVA, IVA
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 385 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic…
- Trial name
- NCT07859085
- Testing
- GDC-7035, Panitumumab, mFOLFOX6
- Volunteers
- 388 people
- Sponsor
- Genentech, Inc.
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Neuroendocrine Tumors, NET
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with…
- Conditions
- Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NCT05997056
- Testing
- nab-sirolimus
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aadi Bioscience, Inc.
Chronic Pancreatitis
A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain
The purpose of this study is to evaluate two different treatments in subjects with chronic pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain.
- Trial name
- EUR-1066 (NCT01159119)
- Testing
- EUR-1066-A, Zenpep, EUR-1066-B
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Forest Laboratories
Metabolic Disorder; Carbohydrate, Absorption, Intestine
Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.
This study aimed at determining the 4-hours postprandial blood glucose and insulin responses to the ingestion of cereal product differing by their SDS content.
- Trial name
- NCT02538653
- Testing
- Sandwich biscuit high in SDS, Co-extruded cereal low in SDS
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Pancreatic Cancer
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.
- Trial name
- NCT02854072
- Testing
- GV1001, Gemcitabine, Capecitabine
- Where
- 16 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.